Renal Adjuvant MultiPle Arm Randomised Trial

This study is looking for people who have had kidney cancer (renal cell carcinoma) that has been surgically removed. They are specifically interested in patients where there's no visible cancer left after the operation, and who have a moderate to high chance of the cancer coming back.

You would need to have had your surgery between 28 and 91 days before joining the study, and recent scans should show no remaining cancer. Your overall health should be generally good, meaning you can manage your daily activities without too much difficulty. Also, your blood test results, like your blood count and liver function, need to be within a healthy range.

Some types of kidney cancer are not included, and if you have certain other serious health conditions, you might not be able to take part. The research team will carefully check all details from your medical history and recent tests to confirm if you are suitable for the study.

If you decide to take part in this study, you will first undergo a series of assessments, including physical exams, blood tests, and scans, to ensure you meet all the requirements. You will then be randomly assigned to one of three groups: receive durvalumab alone, receive durvalumab and tremelimumab together, or continue with the usual monitoring approach.

If you are in one of the treatment groups, the drugs will be given through a drip (intravenously) at specific intervals. The exact schedule for these infusions will be explained to you in detail by the study team. You will have regular follow-up appointments, which will include physical examinations, blood tests, and scans, to monitor your health and check for any signs of the cancer returning or any side effects from the treatment. These visits will be scheduled over a period of time, similar to what you would experience with standard monitoring. The total duration of active treatment and follow-up will depend on the specific treatment plan and is part of a multi-year study.